[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results].
Boyko AN, Bakhtiyarova KZ, Boyko OV, Dudin VA, Zaslavskii LG, Malkova NA, Parshina EV, Poverennova IY, Sivertseva SA, Totolyan NA, Shchur SG, Khabirov FA, Goncharova ZA, Zakharova MN, Bolsun DD, Zinkina-Orikhan AV, Lin'kova YN, Chernovskaya TV, Porozova AA.
Boyko AN, et al. Among authors: boyko ov.
Zh Nevrol Psikhiatr Im S S Korsakova. 2023;123(2):52-59. doi: 10.17116/jnevro202312302152.
Zh Nevrol Psikhiatr Im S S Korsakova. 2023.
PMID: 36843459
Clinical Trial.
Russian.